In vitro evaluation of differences in phase 1 metabolism of ketamine and other analgesics among humans, horses, and dogs.

The research focused on the differences in how ketamine and other pain-relievers are metabolized in humans, horses, and dogs, and how this process might affect their interactions when given together.

Objective and Methodology

• The study was guided by the aim to determine the role of cytochrome P450 (CYP) enzymes in metabolizing ketamine in different species, and to understand how other pain medications affect this process.
• Liver microsomes, which are structures found within cells, were sourced from humans, horses, and dogs for the study.
• The researchers applied a testing technique where an analgesic and particular substrates, related to either CYP 3A4 or CYP 2C9, were incubated simultaneously with the liver microsomes.
• The luminescence emitted by this collaboration was then measured and contrasted with a control sample.
• Finally, the researchers utilized capillary electrophoresis, a separation technique, to recognize and quantify ketamine and its derivative, norketamine.

Results

• A decrease in luminescence signal, associated with metabolic engagement, occurred in a concentration-dependent manner for ibuprofen and diclofenac when studied with CYP 2C9 in human and equine liver microsomes. However, this effect was not seen with CYP 3A4 or with the analgesics methadone or xylazine in any species.
• The presence of methadone or xylazine alongside ketamine led to a reduced formation of norketamine in horse and dog liver microsomes, but not in humans. Norketamine formation remained unaltered by ibuprofen in all species, but was diminished by diclofenac in human liver microsomes.
• The rate of metabolic activity was highest for S-ketamine, a form of ketamine, in horse liver microsomes compared to other analgesics.

Conclusions

• The analyzed data confirmed that the CYP 3A4 enzyme family and homologues of CYP 2C9 play significant roles in ketamine metabolism in humans, horses, and dogs.
• Methadone and xylazine were found to inhibit the process of ketamine metabolism under laboratory conditions, suggesting that administering ketamine with these analgesics could lead to increased ketamine concentrations and reduced clearance of ketamine from the body, potentially contributing to undesired effects.